These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6220198)

  • 1. Combination chemotherapy pneumonitis: a case report of possible synergistic toxicity.
    Goedert JJ; Smith FP; Tsou E; Weiss RB
    Med Pediatr Oncol; 1983; 11(2):116-8. PubMed ID: 6220198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of 5-FU, doxorubicin, and mitomycin (FAM) and chlorozotocin in advanced measureable pancreatic cancer.
    Smith FP; Rustgi VK; Schertz G; Woolley PV; Schein PS
    Cancer Treat Rep; 1982 Dec; 66(12):2095-6. PubMed ID: 6215982
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas.
    Bukowski RM; Abderhalden RT; Hewlett JS; Weick JK; Groppe CW
    Cancer Clin Trials; 1980; 3(4):321-4. PubMed ID: 6448716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible pulmonary toxicity secondary to vinblastine.
    Konits PH; Aisner J; Sutherland JC; Wiernik PH
    Cancer; 1982 Dec; 50(12):2771-4. PubMed ID: 7139567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).
    Oster MW; Gray R; Panasci L; Perry MC
    Cancer; 1986 Jan; 57(1):29-33. PubMed ID: 2934124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary disease as a complication of chlorozotocin chemotherapy.
    Ahlgren JD; Smith FP; Kerwin DM; Sikic BI; Weiner JH; Schein PS
    Cancer Treat Rep; 1981; 65(3-4):223-9. PubMed ID: 6453644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma.
    Bukowski RM; Schacter LP; Groppe CW; Hewlett JS; Weick JK; Livingston RB
    Cancer; 1982 Jul; 50(2):197-200. PubMed ID: 6211223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.
    Moertel CG; Lefkopoulo M; Lipsitz S; Hahn RG; Klaassen D
    N Engl J Med; 1992 Feb; 326(8):519-23. PubMed ID: 1310159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed beam radiotherapy and combination chemotherapy in localized pancreatic adenocarcinoma-preliminary results.
    Bukowski RM; Gahbauer R; Rodriquez-Antunez A; Hermann R
    Int J Radiat Oncol Biol Phys; 1982 Jul; 8(7):1231-3. PubMed ID: 6214533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholestatic jaundice associated with chlorozotocin.
    Belt RJ; McGregor D; Haas CD; Bhatia PS
    Cancer Treat Rep; 1980; 64(12):1235-9. PubMed ID: 6451288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility study of combining metronidazole with chemotherapy.
    Stewart DJ; Maroun JA; Young V; Crook AF; Hopkins HS; Yan RC; Richard MT; Hugenholtz H; Bélanger R; Heringer R
    J Clin Oncol; 1983 Jan; 1(1):17-23. PubMed ID: 6422002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of sequential addition of the nitrosourea, chlorozotocin, to the FAM combination in advanced gastric cancer.
    Gisselbrecht C; Smith FP; MacDonald JS; Korsmeyer SJ; Boiron M; Woolley PV; Schein PS
    Cancer; 1983 May; 51(10):1792-4. PubMed ID: 6219735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group.
    Cancer Treat Rep; 1985 Apr; 69(4):417-20. PubMed ID: 2859924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer.
    Wiggans RG; Woolley PV; Macdonald JS; Smythe T; Ueno W; Schein PS
    Cancer; 1978 Feb; 41(2):387-91. PubMed ID: 147131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study.
    Theodors A; Bukowski RM; Hewlett JS; Livingston RB; Weick JK
    Am J Clin Oncol; 1982 Oct; 5(5):555-8. PubMed ID: 6217742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma.
    Kelsen D; Hudis C; Niedzwiecki D; Dougherty J; Casper E; Botet J; Vinciguerra V; Rosenbluth R
    Cancer; 1991 Sep; 68(5):965-9. PubMed ID: 1833042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interstitial pneumonitis associated with mitomycin C and DTIC: a case report.
    Yoon JM; Rao U; Vassilopoulos PP; Ledesma E; Mittelman A
    Med Pediatr Oncol; 1981; 9(1):61-7. PubMed ID: 7464693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic drug-induced pulmonary disease: update 1980.
    Weiss RB; Muggia FM
    Am J Med; 1980 Feb; 68(2):259-66. PubMed ID: 6153504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silent renal microangiography after mitomycin C therapy.
    Poch E; González-Clemente JM; Torras A; Darnell A; Botey A; Revert L
    Am J Nephrol; 1990; 10(6):514-7. PubMed ID: 2127509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interstitial pneumonia from mitomycin.
    Orwoll ES; Kiessling PJ; Patterson JR
    Ann Intern Med; 1978 Sep; 89(3):352-5. PubMed ID: 686548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.